For example, CCR7-modified MSCs have demonstrated clinical efficacy in mouse models of GVHD, while CXCR5-modified MSCs have been found to effectively migrate to injured sites by binding to CXCL13, which is highly expressed in damaged tissues [132,133,134]. This evidence concerns the gene CXCR5 and graft versus host disease.